Breast Cancer
Conditions
Keywords
Cancer, Breast, 18FDG, Axillary, Positron Emission Tomography
Brief summary
The primary endpoint of this study is to show that this algorithm in high definition is superior to the classical algorithm in the diagnosis of lymph node metastases.
Interventions
None listed
Sponsors
Centre Francois Baclesse
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed consent and signed by the patient * Age ≥ 18 years * Breast tumor for which the therapeutic indication for surgery has from the outset: breast surgery (conservative or radical) associated with a conventional axillary dissection * Proof of infiltrating ductal carcinoma histology * No known metastasis * No cons-indication to anesthesia.
Exclusion criteria
* History of neoadjuvant therapy * Patients with invasive lobular carcinoma * Indication of the use of sentinel node (if invasive carcinoma uni-centric, ≤ 2 cm in diameter, without palpable lymphadenopathy (N0)) * Diabetes is not controlled by conventional treatment (blood glucose\> 1.8 g / l) * Inability to capital * Patients who are pregnant or nursing or of childbearing potential and not using adequate contraception * Persons deprived of their liberty * Major subject of a measure of legal protection or unable to consent * Refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance of FDG-PET for the evaluation of nodal status | 3 years | Show that the algorithm of high-definition positron emission tomography (PET) to 18Fluoro-deoxy-glucose (18FDG) is greater than a classical algorithm in the diagnosis of lymph node metastases. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Information on lymph node status in patients with breast cancer. | 3 years | Show that scintigraphy performed on a FDG positron camera equipped with a reconstruction algorithm for high-definition can provide reliable information on lymph node status in patients with breast cancer and determine the minimum size of lymph node metastatic lesions. |
Countries
France
Outcome results
None listed